G H Jackson
Overview
Explore the profile of G H Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
689
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giles H, Drayson M, Kishore B, Pawlyn C, Kaiser M, Cook G, et al.
Blood Cancer J
. 2024 Mar;
14(1):50.
PMID: 38499538
Deeper responses are associated with improved survival in patients being treated for myeloma. However, the sensitivity of the current blood-based assays is limited. Historical studies suggested that normalisation of the...
2.
Jones J, Barber A, Le Bihan Y, Weinhold N, Ashby C, Walker B, et al.
Leukemia
. 2021 Aug;
35(10):3017-3020.
PMID: 34373585
No abstract available.
3.
Went M, Sud A, Law P, Johnson D, Weinhold N, Forsti A, et al.
Blood Cancer J
. 2017 Jun;
7(6):e573.
PMID: 28622301
No abstract available.
4.
Shah V, Sherborne A, Walker B, Johnson D, Boyle E, Ellis S, et al.
Leukemia
. 2017 Jun;
32(1):102-110.
PMID: 28584253
Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations...
5.
Pawlyn C, Bright M, Buros A, Stein C, Walters Z, Aronson L, et al.
Blood Cancer J
. 2017 Apr;
7(3):e549.
PMID: 28362441
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for...
6.
Jones J, Cairns D, Gregory W, Collett C, Pawlyn C, Sigsworth R, et al.
Blood Cancer J
. 2016 Dec;
6(12):e506.
PMID: 27935580
We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here...
7.
Johnson D, Weinhold N, Mitchell J, Chen B, Stephens O, Forsti A, et al.
Leukemia
. 2015 Dec;
30(4):883-8.
PMID: 26669972
A major complication of multiple myeloma (MM) is the development of osteolytic lesions, fractures and bone pain. To identify genetic variants influencing the development of MM bone disease (MBD), we...
8.
Sava G, Speedy H, Di Bernardo M, Dyer M, Holroyd A, Sunter N, et al.
Leukemia
. 2014 Nov;
29(3):748-51.
PMID: 25363670
No abstract available.
9.
Boyd K, Ross F, Chiecchio L, Dagrada G, Konn Z, Tapper W, et al.
Leukemia
. 2011 Aug;
26(2):349-55.
PMID: 21836613
The association of genetic lesions detected by fluorescence in situ hybridization (FISH) with survival was analyzed in 1069 patients with newly presenting myeloma treated in the Medical Research Council Myeloma...
10.
Cook G, Jackson G, Morgan G, Russell N, Kirkland K, Lee J, et al.
Bone Marrow Transplant
. 2010 Nov;
46(9):1210-8.
PMID: 21102497
Auto-SCT is the standard first-line consolidative therapy in patients with multiple myeloma (MM). We performed a national benchmarking outcome analysis for patients with MM who underwent a single auto-SCT in...